Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 22:15:2137-2157.
doi: 10.2147/IDR.S318322. eCollection 2022.

Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence

Daniele Roberto Giacobbe  1   2 , Silvia Dettori  1   2 , Silvia Corcione  3 , Antonio Vena  1   2 , Chiara Sepulcri  1   2 , Alberto Enrico Maraolo  4 , Francesco Giuseppe De Rosa  3 , Matteo Bassetti  1   2
Affiliations
Review

Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence

Daniele Roberto Giacobbe et al. Infect Drug Resist. .

Abstract

Staphylococcus aureus remains an important human pathogen of concern, with mortality rates surpassing 30% in the case of severe systemic infections. Distinguishing methicillin-susceptible S. aureus from methicillin-resistant S. aureus (MRSA) is fundamental for therapeutic choices. A crucial emerging concept in the treatment of acute bacterial skin and skin structure infections is the availability of various approved agents with anti-MRSA activity, which allow a personalized approach based on the characteristics of any given patient while at the same time remaining in line with high certainty efficacy evidence from large randomized controlled trials. Regarding the treatment of S. aureus bloodstream infections (BSI), interesting aspects that may become relevant in the near future are the presence of both old and novel agents in phase-2 or phase-3 of clinical development for this indication, and the pressing need for high certainty evidence to guide the possible use of combination therapy in specific categories or phenotypes of patients with complicated MRSA BSI.

Keywords: ABSSSI; BSI; MRSA; MSSA; Staphylococcus aureus; bacteremia.

PubMed Disclaimer

Conflict of interest statement

Outside the submitted work, DRG reports investigator-initiated grants from Pfizer Inc, Shionogi, and Gilead Italia. Outside the submitted work, MB reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. The other authors report no conflicts of interest relevant to this paper.

Figures

Figure 1
Figure 1
Proposed clinical reasoning for the empirical treatment of MRSA acute bacterial skin and skin structure infections.
Figure 2
Figure 2
Proposed clinical reasoning for the treatment of MRSA bloodstream infections.
See this image and copyright information in PMC

References

    1. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–59. doi:10.1086/345476 - DOI - PubMed
    1. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25(2):362–386. doi:10.1128/CMR.05022-11 - DOI - PMC - PubMed
    1. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol. 2016;37(11):1288–1301. doi:10.1017/ice.2016.174 - DOI - PMC - PubMed
    1. Bassetti M, Labate L, Melchio M, et al. Current pharmacotherapy for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Expert Opin Pharmacother. 2021;4:1–15. - PubMed
    1. Wolkewitz M, Frank U, Philips G, Schumacher M, Davey P, Group BS. Mortality associated with in-hospital bacteraemia caused by Staphylococcus aureus: a multistate analysis with follow-up beyond hospital discharge. J Antimicrob Chemother. 2011;66(2):381–386. doi:10.1093/jac/dkq424 - DOI - PubMed

LinkOut - more resources